141 related articles for article (PubMed ID: 19142122)
1. A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study design.
Llorca PM; Bodkin JA; Spann M; Ball SG; Russell JM; Ball SG
J Clin Psychopharmacol; 2009 Feb; 29(1):96-7. PubMed ID: 19142122
[No Abstract] [Full Text] [Related]
2. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
[TBL] [Abstract][Full Text] [Related]
3. The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials.
Beesdo K; Hartford J; Russell J; Spann M; Ball S; Wittchen HU
J Anxiety Disord; 2009 Dec; 23(8):1064-71. PubMed ID: 19643572
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
Allgulander C; Hartford J; Russell J; Ball S; Erickson J; Raskin J; Rynn M
Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
[TBL] [Abstract][Full Text] [Related]
5. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression.
Nelson JC
J Clin Psychopharmacol; 2011 Oct; 31(5):682-4. PubMed ID: 21881463
[No Abstract] [Full Text] [Related]
6. Duloxetine in the treatment of generalized anxiety disorder.
Kornstein SG; Russell JM; Spann ME; Crits-Christoph P; Ball SG
Expert Rev Neurother; 2009 Feb; 9(2):155-65. PubMed ID: 19210191
[TBL] [Abstract][Full Text] [Related]
7. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
8. Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder.
Bodkin JA; Allgulander C; Llorca PM; Spann ME; Walker DJ; Russell JM; Ball SG
Hum Psychopharmacol; 2011 Apr; 26(3):258-66. PubMed ID: 21678494
[TBL] [Abstract][Full Text] [Related]
9. Trazodone in the treatment of psychoneuroses: a double-blind study.
Antonelli F; De Gregorio M; Dionisio A
Curr Ther Res Clin Exp; 1973 Oct; 15(10):799-804. PubMed ID: 4201978
[No Abstract] [Full Text] [Related]
10. The mousetrap: managing the placebo effect in antidepressant trials.
Lakoff A
Mol Interv; 2002 Apr; 2(2):72-6. PubMed ID: 14993352
[No Abstract] [Full Text] [Related]
11. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression.
Howland RH; Wilson MG; Kornstein SG; Clayton AH; Trivedi MH; Wohlreich MM; Fava M
Ann Clin Psychiatry; 2008; 20(4):209-18. PubMed ID: 19034753
[TBL] [Abstract][Full Text] [Related]
12. A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant.
Mallinckrodt C; Chuang-Stein C; McSorley P; Schwartz J; Archibald DG; Perahia DG; Detke MJ; Alphs L
Pharm Stat; 2007; 6(1):9-22. PubMed ID: 17238129
[TBL] [Abstract][Full Text] [Related]
13. Does duloxetine safely and effectively reduce the severity of diabetic peripheral neuropathic pain?
Russell JW
Nat Clin Pract Neurol; 2006 Jan; 2(1):18-9. PubMed ID: 16932514
[No Abstract] [Full Text] [Related]
14. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial.
Feltner D; Hill C; Lenderking W; Williams V; Morlock R
J Psychiatr Res; 2009 Oct; 43(15):1224-30. PubMed ID: 19423131
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
16. [Results of the clinical testing of amitriptylin and C 34,276-Ba (dibenzobicyclooctadiene derivative) in a double-blind study].
Bruck J; Söllner E; Tschabitscher H
Nervenarzt; 1974 Sep; 45(9):492-6. PubMed ID: 4612394
[No Abstract] [Full Text] [Related]
17. Does pain cause the perception of fatigue in patients with chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.
Fishbain DA; Hall JA; Risser RC; Gonzales JS
Pain Pract; 2009; 9(5):354-62. PubMed ID: 19500272
[TBL] [Abstract][Full Text] [Related]
18. Amoxapine: a double-blind evaluation of antidepressant activity.
Gallant DM; Swanson WC; Mielke DH; Guerrero-Figueroa R; Collins H
Curr Ther Res Clin Exp; 1973 Feb; 15(2):56-9. PubMed ID: 4632507
[No Abstract] [Full Text] [Related]
19. Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study.
Kelin K; Berk M; Spann M; Sagman D; Raskin J; Walker D; Perahia D
Int J Clin Pract; 2010 May; 64(6):719-26. PubMed ID: 20345508
[TBL] [Abstract][Full Text] [Related]
20. Treatment of seasonal affective disorder with duloxetine: an open-label study.
Pjrek E; Willeit M; Praschak-Rieder N; Konstantinidis A; Semlitsch HV; Kasper S; Winkler D
Pharmacopsychiatry; 2008 May; 41(3):100-5. PubMed ID: 18484551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
